DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PALBOCICLIB

« Back to Dashboard

Clinical Trials for Palbociclib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00141297	A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer	Completed	Pfizer	Phase 1	2004-09-01	PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
NCT00420056	An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.	Completed	Pfizer	Phase 1	2007-05-01	This is a pilot study evaluating tumor activity using Positron Emission Tomography, which is also known as a "PET scan". This study will assess the safety of using PD-0332991 in patients with mantle cell lymphoma.
NCT00555906	An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.	Completed	Pfizer	Phase 2	2008-01-01	This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® [bortezomib] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
NCT00721409	Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer	Active, not recruiting	Pfizer	Phase 1/Phase 2	2008-09-01	The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer

Clinical Trial Conditions for Palbociclib

Condition Name

Condition Name for Palbociclib
Intervention	Trials
Breast Cancer	37
Metastatic Breast Cancer	23
Healthy	14
Breast Neoplasms	9

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Palbociclib
Intervention	Trials
Breast Neoplasms	98
Neoplasms	15
Carcinoma	11
Head and Neck Neoplasms	8

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Palbociclib

Trials by Country

Trials by Country for Palbociclib
Location	Trials
United States	525
Spain	37
Japan	35
Italy	31
Canada	30

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Palbociclib
Location	Trials
California	27
New York	26
Massachusetts	25
Tennessee	23
Texas	22

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Palbociclib

Clinical Trial Phase

Clinical Trial Phase for Palbociclib
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	18
Phase 2/Phase 3	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Palbociclib
Clinical Trial Phase	Trials
Recruiting	84
Not yet recruiting	55
Completed	21

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Palbociclib

Sponsor Name

Sponsor Name for Palbociclib
Sponsor	Trials
Pfizer	100
National Cancer Institute (NCI)	14
AstraZeneca	10

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Palbociclib
Sponsor	Trials
Other	182
Industry	148
NIH	14

Export unavailable in trial.
Subscribe for complete access.